hit counter

Esketamine Failed Cost-Effectiveness vs. Cheaper TRD Options at $50K/QALY

Photoreal illustration of a depression-treatment decision with cost and outcome imagery, conveying healthcare-economic decision-making.

Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …

Read more

Copy Number Variants Did Not Moderate ADHD or Autism Outcomes in ALSPAC

Photoreal illustration of DNA strands and developmental timeline overlaid on a schematic young adult, conveying genetic moderation of childhood neurodevelopmental outcomes.

A 2026 ALSPAC analysis tested a narrow claim behind routine genetic screening for childhood attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): whether rare copy number variants (CNVs; deleted or duplicated DNA segments) make young-adult outcomes worse than ADHD/ASD status alone would predict. In 8,414 people with usable CNV data, ADHD and ASD predicted worse …

Read more

Cognitive Reserve in First-Episode Psychosis: Education PRS Adds 4.2%

Photoreal illustration of brain with strengthening neural networks suggesting reserve and protection against cognitive decline.

A 2026 analysis of 174 people with non-affective first-episode psychosis found that cognitive reserve was tied to 3 signals available near illness onset: age at onset, family history of psychosis, and polygenic liability for educational attainment. Adding the education polygenic score raised the model’s adjusted R² from 13.5% to 17.7%, a real but modest gain …

Read more

1 mg Guanfacine for Self-Harm Thoughts in ADHD-PTSD-BPD Case

MHD featured image for 1 mg guanfacine and self-harm thoughts in complex ADHD, PTSD, BPD, and ASD comorbidity.

A 2026 case report linked 1 mg nightly guanfacine modified-release to first-ever cessation of intrusive deliberate self-harm thoughts in a 16-year-old with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) traits, borderline personality disorder (BPD) traits, and post-traumatic stress disorder (PTSD). The same case became more interesting after the patient stopped taking guanfacine and the self-harm …

Read more